LRI Investments LLC Raises Holdings in Sanofi (NASDAQ:SNY)

LRI Investments LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 18,685.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,387 shares of the company’s stock after purchasing an additional 6,353 shares during the quarter. LRI Investments LLC’s holdings in Sanofi were worth $310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Boston Partners lifted its position in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 16.5% during the 1st quarter. Bank of New York Mellon Corp now owns 7,224,508 shares of the company’s stock valued at $351,111,000 after acquiring an additional 1,021,077 shares during the last quarter. Mondrian Investment Partners LTD increased its position in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the last quarter. Raymond James & Associates lifted its position in Sanofi by 16.2% during the second quarter. Raymond James & Associates now owns 2,689,876 shares of the company’s stock valued at $130,513,000 after purchasing an additional 374,621 shares during the last quarter. Finally, Equity Investment Corp grew its stake in shares of Sanofi by 23.0% in the 1st quarter. Equity Investment Corp now owns 2,393,474 shares of the company’s stock worth $116,323,000 after buying an additional 447,872 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the topic of several analyst reports. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 18th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Up 1.8 %

SNY opened at $56.21 on Friday. The stock’s fifty day moving average is $51.02 and its two-hundred day moving average is $49.08. The company has a market capitalization of $142.36 billion, a P/E ratio of 28.25, a PEG ratio of 1.56 and a beta of 0.59. Sanofi has a 52 week low of $42.63 and a 52 week high of $56.32. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $0.95 EPS. Analysts forecast that Sanofi will post 4.19 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.